Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Messenger Biopharma has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is being reviewed by 1 distinct examiner, VYAS, KEYUR ANILKUMAR. The prosecution is localized in a distinct art unit, indicating a specialized technical focus for the company. VYAS, KEYUR ANILKUMAR is the busiest examiner, as he is responsible for the busiest examiner pending action.
The concentration in a distinct art unit and 1 distinct examiner suggests a streamlined prosecution path. This 1 pending office action is the only active matter currently under review for the portfolio. Practitioners should note that the assignment to a distinct art unit often implies a very specific technical classification for the company's biotech innovations.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| VYAS, KEYUR ANILKUMAR | 1 | 49.4% | +60.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17055061 | SUBSTITUTION OF THE MESSENGER RNA CAP WITH TWO RNA SEQUENCES INTRODUCED AT THE 5-PRIME END THEREOF | VYAS, KEYUR ANILKUMAR | 81d overdue |
| Art Unit | Apps |
|---|---|
| 1637 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17055061 | SUBSTITUTION OF THE MESSENGER RNA CAP WITH TWO RNA SEQUENCES INTRODUCED AT THE 5-PRIME END THEREOF | VYAS, KEYUR ANILKUMAR | 1637 | §103 | Final Rejection | 81d overdue | Pending | Nov 12, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial